Travere Therapeutics (TVTX) Stock Price, News & Analysis

Company Overview

Travere Therapeutics, Inc. (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S. Food and Drug Administration for the treatment of adult and pediatric patients with focal segmental glomerulosclerosis (FSGS). Travere is also pursuing regulatory submissions for sparsentan in immunoglobulin A nephropathy (IgAN), with ongoing clinical trials exploring its long-term safety and efficacy. In addition to its renal pipeline, Travere has expanded its portfolio through a collaboration with Reata Therapeutics to develop anion transport modulators for pediatric cystic fibrosis.

Originally known as Retrophin, the company rebranded as Travere Therapeutics in December 2020 to better reflect its specialized focus on rare kidney diseases. Since the rebranding, Travere has advanced multiple late‐stage clinical programs and established a commercial infrastructure to support the launch and distribution of its therapies. The company maintains partnerships with academic research centers, patient advocacy organizations and global regulatory bodies to accelerate development timelines.

Headquartered in San Diego, Travere serves patients primarily in the United States while conducting clinical trials and seeking regulatory approvals in Europe and other international markets. The company’s leadership team is led by President and Chief Executive Officer Stacy Ennis, who brings extensive experience in biotechnology and rare disease drug development. Under her direction, Travere continues to build its pipeline and support communities impacted by rare and serious conditions.

Key Stats

• Today's Range: $42.50 to $44.50
• 50-Day Range: $26.79 to $44.80
• 52-Week Range: $13.88 to $48.61
• Volume: 1.15 million shs
• Average Volume: 2.15 million shs
• Market Capitalization: $4.12 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $47.83
• Consensus Rating: Moderate Buy

Travere Therapeutics Stock Analysis - MarketRank™

Travere Therapeutics scored higher than 42% of companies evaluated by MarketBeat, and ranked 717th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Travere Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on no strong buy ratings, 10 buy ratings, 2 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Travere Therapeutics is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Travere Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Travere Therapeutics are expected to grow in the coming year, from ($0.16) to $1.46 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Travere Therapeutics is -189.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Travere Therapeutics is -189.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Travere Therapeutics has a P/B Ratio of 34.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for TVTX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Travere Therapeutics does not currently pay a dividend.

Dividend Growth

Travere Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.73

News Sentiment

Travere Therapeutics has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 23 news articles for Travere Therapeutics this week, compared to 5 articles on an average week.

Search Interest

22 people have searched for TVTX on MarketBeat in the last 30 days. This is an increase of 450% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added Travere Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Travere Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,890,666.00 in company stock.

Percentage Held by Insiders

4.44% of the stock of Travere Therapeutics is held by insiders.

Percentage Held by Institutions

Travere Therapeutics has minimal institutional ownership at this time.

TVTX Stock Analysis - Frequently Asked Questions

How have TVTX shares performed this year?

Travere Therapeutics' stock was trading at $38.21 at the start of the year. Since then, TVTX shares have increased by 14.7% and is now trading at $43.82.

How were Travere Therapeutics' earnings last quarter?

Travere Therapeutics, Inc. (NASDAQ:TVTX) announced its quarterly earnings data on Monday, May, 4th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.29. Travere Therapeutics's quarterly revenue was up 55.6% on a year-over-year basis.
Read the conference call transcript.

Who are Travere Therapeutics' major shareholders?

Travere Therapeutics' top institutional shareholders include Stephens Investment Management Group LLC (1.95%), Emerald Advisers LLC (1.69%), Emerald Mutual Fund Advisers Trust (1.02%) and Pictet Asset Management Holding SA (0.57%). Insiders that own company stock include Eric M Dube, Peter Heerma, Christopher R Cline, William E Rote, Jula Inrig, Elizabeth E Reed, Jeffrey A Meckler, Gary A Lyons, Timothy Coughlin, Sandra Calvin and Roy D Baynes.
View institutional ownership trends.

How do I buy shares of Travere Therapeutics?

Shares of TVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Travere Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Travere Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Home Depot (HD), Netflix (NFLX), Advanced Micro Devices (AMD) and Cisco Systems (CSCO).

Company Calendar

• Last Earnings: 5/04/2026
• Today: 5/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TVTX
• CIK: 1438533
• Web: www.retrophin.com
• Phone: (888) 969-7879
• Fax: 302-645-1280
• Employees: 460
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Travere Therapeutics: $47.83
• High Price Target: $60.00
• Low Price Target: $25.00
• Potential Upside/Downside: +8.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.69
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$25.55 million
• Net Margins: -4.00%
• Pretax Margin: -10.04%
• Return on Equity: -28.38%
• Return on Assets: -3.69%

Debt

• Debt-to-Equity Ratio: 2.71
• Current Ratio: 2.74
• Quick Ratio: 2.70

Sales & Book Value

• Annual Sales: $490.73 million
• Price / Sales: 8.33
• Cash Flow: $0.36 per share
• Price / Cash Flow: 124.01
• Book Value: $1.28 per share
• Price / Book: 34.58

Miscellaneous

• Outstanding Shares: 92,370,000
• Free Float: 88,269,000
• Market Cap: $4.09 billion
• Optionable: Optionable
• Beta: 1.13